|
GB0900692D0
|
|
Tools and methods for the stratification of patients with inflammatory disorders
|
|
US2009111782A1
|
|
Composition and methods relating to glucocorticoid receptor-alpha and peroxisome proliferator-activated receptors
|
|
GB0817908D0
|
|
Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
|
|
GB0815857D0
|
|
A scoring system to monitor natural or drug-modified disease progression in "erosive osteoarthritis" of the interphalangeal finger joints
|
|
GB0813518D0
|
|
An optimized scoring system to monitor natural or drug-modified disease progression in erosive osteoarthritis of the interphalangeal finger joints
|
|
GB0811993D0
|
|
Development and use of a safe and effective salmonella vaccine for poultry
|
|
GB0811278D0
|
|
Permissive cells and uses thereof
|
|
GB0811276D0
|
|
Viral inactivation process
|
|
US2010216116A1
|
|
Viral latency model
|
|
GB0809898D0
|
|
Methods and compositions in the treatment of coronaviruses
|
|
GB0807305D0
|
|
Compounds for use in therapy
|
|
GB0807306D0
|
|
Adjuvants for use in vaccination
|
|
GB0803779D0
|
|
Viral inactivation process
|
|
GB0803668D0
|
|
Mucositis therapy
|
|
GB0803076D0
|
|
Mucosal Membrane Receptor and uses thereof
|
|
GB0720502D0
|
|
Markers of matrix gene expression and cellular differentiation in chondrocytes
|
|
GB0718991D0
|
|
Methods and compositions to treat aquatic organisms
|
|
GB0712160D0
|
|
Methods and compositions in the treatment of procine circoviral infection
|
|
US2008319461A1
|
|
Sutureless vessel anastomosis method and apparatus
|
|
EP2037966A2
|
|
Sialoadhesin-related compositions and methods
|
